The EU Drugs Strategy (2013-2020) RSS
A multiannual EU Drugs Strategy (the current one covers the period 2013-2020) sets out the priorities and objectives for the action on drugs of EU countries, the Commission and other EU Institutions and bodies.
The Council endorsed the EU Drugs Strategy (2013-2020) on 7 December 2012. The aim of this strategy is:
- to contribute to a reduction in drug demand and drug supply within the EU, as well as a reduction as regards the health and social risks and harms caused by drugs.
The Strategy is centred around two pillars: drug demand reduction and drug supply reduction . These are complemented with three cross-cutting themes that represent the horizontal nature of the drugs problem:
Two successive EU Drugs Action Plans, covering the period 2013-2016 and 2017-2020 respectively, set out concrete actions to implement the EU Drugs Strategy: EU Action Plan on Drugs (2013-2016) and the EU Action Plan on Drugs (2017-2020).
Evaluation of the EU Drugs Strategy 2005-2012 and its Action Plans
The EU Drugs Strategy 2005-2012 and its implementing Action Plans were the subject of an independent, external evaluation, which the Commission commissioned. The European Monitoring Centre for Drug and Drug Addiction (EMCDDA), the European External Action Service (EEAS), Europol, as well as government and non-government bodies in EU countries, provided input for the evaluation report, which was published in March 2012.
The evaluation showed that the Strategy has clear added value for the EU, for the following reasons:
- it provides for a common and evidence-based framework to tackle the drugs phenomenon both within the European Union and at international level;
- it promotes a shared model with defined priorities, objectives, actions, and tools for evaluation on which Member States can build their own drugs policies; third countries are also increasingly "inspired" by the EU model;
- it provides for a forum for consensus building and decision making and a platform for sharing information and for mutual learning; control of drug precursors demonstrates EU's added value and ability to legislate and coordinate;
- it enhances the EU’s 'voice' in international fora and promotes a culture of harmonised data collection and best practices identification;
- implementation of harm reduction measures and their apparent effectiveness is seen as the key area of the Strategy's influence.
The EU Action Plan on Drugs (2013-2016)
Today it is the EU Action Plan on Drugs which provides the road map for the EU. There are five priority areas:
- improving coordination and cooperation among all those involved in EU drugs policy: EU governments, the European Commission, the European Parliament, the EEAS, EU agencies, civil society, international organisations and countries outside the EU;
- contributing to a measurable reduction in the use of illicit drugs, in problem drug use, in drug dependence and in drug-related health and social harms, as well as contributing to a delay in the onset of drug use ;
- contributing to a measurable reduction of the availability and supply of illicit drugs in the EU;
- improving international cooperation through strengthening dialogue and cooperation between the EU and third countries and international organisations on drugs issues in a comprehensive and balanced manner;
- contributing to a better understanding of all aspects of the drugs phenomenon and of the impact of measures in order to provide sound and comprehensive evidence for policies and actions.